- Home
- GAMB vs CRBP Comparison
GAMB vs CRBP Comparison
Compare GAMB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | CRBP |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 170.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAMB | CRBP |
|---|---|---|
| Price | $4.99 | $8.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $9.79 | ★ $50.29 |
| AVG Volume (30 Days) | ★ 511.9K | 171.0K |
| Earning Date | 11-13-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $154,519,000.00 | N/A |
| Revenue This Year | $32.43 | N/A |
| Revenue Next Year | $12.72 | $220.00 |
| P/E Ratio | $102.60 | ★ N/A |
| Revenue Growth | ★ 24.21 | N/A |
| 52 Week Low | $4.60 | $4.64 |
| 52 Week High | $17.14 | $20.56 |
Technical Indicators
Market Signals| Indicator | GAMB | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 52.22 |
| Support Level | $4.74 | $8.05 |
| Resistance Level | $5.07 | $8.66 |
| Average True Range (ATR) | 0.20 | 0.45 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 27.88 | 90.51 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.